AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33188140 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired tumor and plasma ctDNA samples sequenced by target-capture deep sequencing of 1,021 genes.
Number of subjects: 300
Study 33188140 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired tissue and ctDNA analysis.
Number of subjects: 300
Study 33188221 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure ventilation ex situ lung perfusion
Number of subjects: 12
Study 33188254 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower urinary tract symptoms (LUTS)
Number of subjects: 6005
Study 33188254 — intervention group
Group type: EXPERIMENTAL
Intervention: Overactive bladder (OAB)
Number of subjects: 6005
Study 33188254 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 6005
Study 33188272 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone-to-renin ratio (ARR) quartiles
Number of subjects: 545
Study 33188385 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin (100 mg/kg q8h)
Number of subjects: 140
Study 33188413 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal diet Cluster I (high intake of plant protein, fiber, and carbohydrates)
Number of subjects: 120
Study 33188413 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal diet Cluster II (high intake of animal protein and lipids)
Number of subjects: 120
Study 33188413 — intervention group
Group type: COMPARATOR
Intervention: Mode of delivery (C-section) with antibiotic exposure
Number of subjects: 120
Study 33188413 — intervention group
Group type: COMPARATOR
Intervention: Mode of delivery (vaginal birth)
Number of subjects: 120
Study 33188449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological modifications of the actin cytoskeleton
Number of subjects: 0
Study 33188873 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine treatment (43 patients in monocentric cohort, 203 patients in multicentric cohort)
Number of subjects: 435
Study 33188873 — intervention group
Group type: COMPARATOR
Intervention: GemPred+ stratification among gemcitabine-treated patients
Number of subjects: 435
Study 33188997 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib plus R-CHOP
Number of subjects: 21
Study 33189083 — intervention group
Group type: COMPARATOR
Intervention: Melatonin (up to 10 mg)
Number of subjects: 649
Study 33189083 — intervention group
Group type: COMPARATOR
Intervention: Trazodone (50 mg for two weeks)
Number of subjects: 649
Study 33189083 — intervention group
Group type: COMPARATOR
Intervention: Ramelteon (8 mg, phase 2 trial)
Number of subjects: 649
Study 33189083 — intervention group
Group type: COMPARATOR
Intervention: Orexin antagonists (for four weeks)
Number of subjects: 649
Study 33189510 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide receptor radionuclide therapy
Number of subjects: 0
Study 33189510 — intervention group
Group type: COMPARATOR
Intervention: Fixed activity of the radiopharmaceutical
Number of subjects: 0
Study 33189632 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 144
Study 33189854 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric Electrical Stimulation (Enterra therapy)
Number of subjects: 142
Study 33190086 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE) - five single volume plasma exchanges over eight days within a 14-day study period.
Number of subjects: 10
Study 33190518 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-traumatic growth (PTG) recognized through the disclosure process
Number of subjects: 22
Study 33190629 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥50 mL/(kg · day) human milk
Number of subjects: 964
Study 33191112 — intervention group
Group type: EXPERIMENTAL
Intervention: Relebactam/imipenem/cilastatin (250 mg/500 mg/500 mg) dosed every 6 h for 5-14 days
Number of subjects: 81
Study 33191168 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyper-CVAD Regimen
Number of subjects: 0
Study 33191169 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem-cell transplantation (allo-HSCT)
Number of subjects: 0
Study 33191169 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning regimens
Number of subjects: 0
Study 33191169 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttransplantation care
Number of subjects: 0
Study 33191169 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal residual disease measurement and preemptive therapies
Number of subjects: 0
Study 33191282 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain (visual analog scale)
Number of subjects: 379
Study 33191282 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue (visual analog scale)
Number of subjects: 379
Study 33191282 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Assessment Questionnaire (HAQ)
Number of subjects: 379
Study 33191282 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard components of disease activity (SJC/TJC, CRP, ESR, PhGH, PaGH)
Number of subjects: 379
Study 33191407 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV integration signatures
Number of subjects: 272
Study 33191407 — intervention group
Group type: EXPERIMENTAL
Intervention: Episomal HPV in PIK3CA mutated tumours
Number of subjects: 272
Study 33191407 — intervention group
Group type: EXPERIMENTAL
Intervention: High HPV copy number
Number of subjects: 272
Study 33191407 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV genotype
Number of subjects: 272
Study 33191524 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 86
Study 33191769 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Optical Coherence Tomography (OCT) and Cardiac Magnetic Resonance (CMR) imaging
Number of subjects: 301
Study 33191769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance (CMR) imaging
Number of subjects: 301
Study 33191769 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality imaging with coronary OCT and CMR
Number of subjects: 301
Study 33191774 — intervention group
Group type: EXPERIMENTAL
Intervention: F/TDF at 33% of daily dosing
Number of subjects: 48
Study 33191774 — intervention group
Group type: EXPERIMENTAL
Intervention: F/TDF at 67% of daily dosing
Number of subjects: 48
Study 33191774 — intervention group
Group type: EXPERIMENTAL
Intervention: F/TDF at 100% of daily dosing
Number of subjects: 48
Study 33192054 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported experience measures (PREMs)
Number of subjects: 1932
Study 33192054 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical methods from item response theory (IRT)
Number of subjects: 1932
Study 33192400 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Activa PC+ S device stimulation in the supplementary motor area (SMA) and ventral capsule/ventral striatum (VC/VS)
Number of subjects: 1
Study 33192400 — intervention group
Group type: COMPARATOR
Intervention: Cortical stimulation (blinded)
Number of subjects: 1
Study 33192485 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 96
Study 33192485 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Training (COMB)
Number of subjects: 96
Study 33192485 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control Group
Number of subjects: 96
Study 33192504 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone, dosage and duration not specified
Number of subjects: 0
Study 33192504 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Extract, dosage and duration not specified
Number of subjects: 0
Study 33192706 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7203 (two doses)
Number of subjects: 33
Study 33192706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 33192959 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory Probiotic Intervention
Number of subjects: 0
Study 33192959 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33193001 — intervention group
Group type: EXPERIMENTAL
Intervention: sEMG Assessment during Overground Robot-Assisted Gait Training
Number of subjects: 0
Study 33193013 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stage combined embolization and resection
Number of subjects: 0
Study 33193052 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation
Number of subjects: 0
Study 33193052 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal instrumented assessment
Number of subjects: 0
Study 33193052 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33193314 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation/complement factors (C3, C4, C4a, C9, PT, aPTT, fibrinogen, factor II, VIII, and X, D-dimer, antithrombin, protein C, protein S, von-Willebrand factor)
Number of subjects: 90
Study 33193314 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic susceptibility contrast-enhanced MRI
Number of subjects: 90
Study 33193314 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 90
Study 33193670 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of the A allele (27.6%)
Number of subjects: 116
Study 33194177 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation profiling using Reduced Representation Bisulfite Sequencing (RRBS) in CD04
Number of subjects: 0
Study 33194595 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccination
Number of subjects: 21
Study 33194670 — intervention group
Group type: EXPERIMENTAL
Intervention: OxyChip Implantation
Number of subjects: 24
Study 33194670 — intervention group
Group type: EXPERIMENTAL
Intervention: Electron Paramagnetic Resonance Oximetry
Number of subjects: 24
Study 33194700 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Number of subjects: 453
Study 33194700 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 453
Study 33194741 — intervention group
Group type: EXPERIMENTAL
Intervention: IRX195183, a RARα-Selective CYP26 Resistant Retinoid
Number of subjects: 0
Study 33194913 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal endoscopic tracheal occlusion (FETO)
Number of subjects: 0
Study 33194913 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (non-FETO)
Number of subjects: 0
Study 33195311 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 33195311 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study 33195457 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker intervention, specific details not available
Number of subjects: 0
Study 33195707 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial meniscectomy (n = 139)
Number of subjects: 321
Study 33195707 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (n = 147)
Number of subjects: 321
Study 33195707 — intervention group
Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 321
Study 33195874 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher frequency point-of-care (POC) viral load (VL) and targeted drug resistance mutation (DRM) testing
Number of subjects: 704
Study 33195874 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 704
Study 33196448 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth app promoting healthy eating habits
Number of subjects: 200
Study 33196448 — intervention group
Group type: COMPARATOR
Intervention: Standard primary care
Number of subjects: 200
Study 33196449 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered intervention with assistance via chat
Number of subjects: 166
Study 33196449 — intervention group
Group type: COMPARATOR
Intervention: Self-administered intervention without assistance via chat
Number of subjects: 166
Study 33196581 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer DES (Synergy)
Number of subjects: 75
Study 33196581 — intervention group
Group type: EXPERIMENTAL
Intervention: Durable polymer DES (Resolute Integrity, Xience, Ion, or Promus)
Number of subjects: 75
Study 33196581 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT discontinuation <6 months after PCI
Number of subjects: 75
Study 33196581 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuming or starting cancer treatment (chemotherapy, radiation therapy, or surgery) after PCI
Number of subjects: 75
Study 33196581 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT interruption
Number of subjects: 75
Study 33196581 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced cancer
Number of subjects: 75
Study 33196581 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of aspirin and early P2Y12 inhibitor discontinuation
Number of subjects: 75
Study 33196758 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirbanibulin ointment 1% (once daily for 3 or 5 days over 25 cm2)
Number of subjects: 198
Study 33196758 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirbanibulin ointment 1% (once daily for 3 or 5 days over 25 or 100 cm2)
Number of subjects: 198
Study 33196758 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirbanibulin ointment 1%
Number of subjects: 198
Study 33196852 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral hopping exercises (6 months)
Number of subjects: 10
Study 33196852 — intervention group
Group type: COMPARATOR
Intervention: Control leg (CL)
Number of subjects: 10
Study 33196868 — intervention group
Group type: EXPERIMENTAL
Intervention: D
Number of subjects: 15
Study 33197289 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin + metronidazole + SRP
Number of subjects: 2664
Study 33197289 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole + SRP
Number of subjects: 2664
Study 33197289 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin + SRP
Number of subjects: 2664
Study 33197289 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin + clavulanate + SRP
Number of subjects: 2664
Study 33197289 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline + SRP
Number of subjects: 2664
Study 33197289 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline + SRP
Number of subjects: 2664
Study 33197289 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin + SRP
Number of subjects: 2664
Study 33197289 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline + SRP versus metronidazole + SRP
Number of subjects: 2664
Study 33197289 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin + SRP versus metronidazole + SRP
Number of subjects: 2664
Study 33197289 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin + SRP versus doxycycline + SRP
Number of subjects: 2664
Study 33197293 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic surgery
Number of subjects: 535
Study 33197293 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 535
Study 33197825 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and exercise program (physiotherapy guided education and group-based or home exercise sessions, biweekly for approximately eight weeks)
Number of subjects: 32
Study 33197825 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and exercise program
Number of subjects: 32
Study 33197925 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-90009
Number of subjects: 35
Study 33197929 — intervention group
Group type: EXPERIMENTAL
Intervention: Letermovir
Number of subjects: 0
Study 33197929 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir
Number of subjects: 0
Study 33197929 — intervention group
Group type: COMPARATOR
Intervention: (val)ganciclovir, foscarnet, cidofovir
Number of subjects: 0
Study 33198536 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Asthma Severity Score (HASS)
Number of subjects: 58
Study 33198536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Respiratory Assessment Measure (PRAM)
Number of subjects: 58
Study 33198536 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry
Number of subjects: 58
Study 33198571 — intervention group
Group type: EXPERIMENTAL
Intervention: Total liquid ventilation (TLV)
Number of subjects: 0
Study 33198571 — intervention group
Group type: COMPARATOR
Intervention: Control (normothermic follow-up)
Number of subjects: 0
Study 33198661 — intervention group
Group type: EXPERIMENTAL
Intervention: Resected malignant carcinoma
Number of subjects: 242
Study 33198661 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign pancreatic disease
Number of subjects: 242
Study 33198661 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced disease (inoperable)
Number of subjects: 242
Study 33198661 — intervention group
Group type: EXPERIMENTAL
Intervention: CK-positive cells in resected malignant cases
Number of subjects: 242
Study 33198661 — intervention group
Group type: EXPERIMENTAL
Intervention: CK-positive cells in advanced disease
Number of subjects: 242
Study 33198661 — intervention group
Group type: EXPERIMENTAL
Intervention: CK-positive cells in benign disease
Number of subjects: 242
Study 33198661 — intervention group
Group type: COMPARATOR
Intervention: Presence of CK-positive cells
Number of subjects: 242
Study 33198671 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg orally once daily in 28-day cycles
Number of subjects: 26
Study 33198674 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic chemotherapy, HIPEC and CRS (conversion therapy group)
Number of subjects: 40
Study 33198674 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and HIPEC (palliative chemotherapy group)
Number of subjects: 40
Study 33198674 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic chemotherapy and HIPEC
Number of subjects: 40
Study 33198695 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary audit
Number of subjects: 0
Study 33198781 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer screening with baseline health questionnaire, spirometry, and low-dose CT scan.
Number of subjects: 2514
Study 33198781 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate model based on age, current smoking status, number of pack-years, presence of dyspnea, wheeze, high-risk occupation, and emphysema extent on LDCT.
Number of subjects: 2514
Study 33198942 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Proton Therapy (IMPT)
Number of subjects: 139
Study 33198942 — intervention group
Group type: COMPARATOR
Intervention: Passive Scattering Proton Therapy (PSPT)
Number of subjects: 139
Study 33199155 — intervention group
Group type: EXPERIMENTAL
Intervention: CPL304110 (pyrazole-benzimidazole derivative)
Number of subjects: 0
Study 33199195 — intervention group
Group type: EXPERIMENTAL
Intervention: Short training sessions for nurses on identifying STEMI patients
Number of subjects: 327
Study 33199195 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical STEMI ECG signs
Number of subjects: 327
Study 33199195 — intervention group
Group type: COMPARATOR
Intervention: Delayed group (D2B>70min)
Number of subjects: 327
Study 33199195 — intervention group
Group type: COMPARATOR
Intervention: Non-delayed group (D2B≤70min)
Number of subjects: 327
Study 33199247 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolut PRO valve
Number of subjects: 60
Study 33199389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cipargamin
Number of subjects: 0
Study 33199389 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33199417 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Number of subjects: 1199
Study 33199417 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 1199
Study 33199417 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide 0.75 mg
Number of subjects: 1199
Study 33199417 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide 1.5 mg
Number of subjects: 1199
Study 33199511 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-Pac followed by epirubicin and cyclophosphamide (EC)
Number of subjects: 56
Study 33199608 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible orientation-defined figures
Number of subjects: 0
Study 33199608 — intervention group
Group type: COMPARATOR
Intervention: Invisible orientation-defined figures
Number of subjects: 0
Study 33199917 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide association study
Number of subjects: 10754
Study 33199917 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic correlation analysis
Number of subjects: 10754
Study 33199917 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene mapping and heritability enrichment
Number of subjects: 10754
Study 33199917 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-target enrichment analysis
Number of subjects: 10754
Study 33199917 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of genetic risks
Number of subjects: 10754
Study 33200126 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk assessment framework for trial activities
Number of subjects: 0
Study 33200126 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance on protective measures
Number of subjects: 0
Study 33200217 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (oral administration, dose-adjusted to maintain a therapeutic range of 6-15 ng/ml for 6 months)
Number of subjects: 20
Study 33200217 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (oral administration)
Number of subjects: 20
Study 33200394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 0
Study 33200394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) without concomitant MTX
Number of subjects: 0
Study 33200394 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (ADA) with concomitant MTX
Number of subjects: 0
Study 33200890 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept
Number of subjects: 86
Study 33200890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 33200900 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Number of subjects: 40
Study 33200900 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 40
Study 33200999 — intervention group
Group type: EXPERIMENTAL
Intervention: FAITH! App
Number of subjects: 9
Study 33201228 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study 33201228 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0